Revolution Medicines, Inc.

More coverage

Chief global commercialization officer Mancini sells $347,402 of RVMD stock

Markets 2 d ago 2 sources

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Markets 20 d ago

Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics

Markets 23 d ago

Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?

Markets 27 d ago also on INCY

Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It

Markets 27 d ago

Nvidia, Meta, Revolution Medicines, Abercrombie, Intuit, Salesforce, Moderna, and More Stocks That Explain Today’s Market

Markets 29 d ago also on NVDA INTU

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?

Markets 30 d ago

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Markets 41 d ago also on ONC

Why Revolution Medicines May Be Big Pharma’s Next Takeover Target

Deals 43 d ago

Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?

Markets 44 d ago

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Markets 45 d ago

High Risk, High Reward: Inside The Revolution Medicines Bull Case

Markets 48 d ago